Loading insider details...
Latest Form 4 (Jul 15, 2026): Disposition to Issuer of 6,281 NUVL shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Jul 15, 2026 | Nuvalent, Inc. (NUVL) | Disposition to Issuer | 6,281 | n/a |
| Jun 18, 2026 | Nuvalent, Inc. (NUVL) | Grant/Award | 3,444 | n/a |
| Jun 3, 2026 | ADC Therapeutics SA (ADCT) | Grant/Award | 45,000 | n/a |
| May 21, 2026 | Travere Therapeutics, Inc. (TVTX) | Grant/Award | 4,000 | n/a |
| Dec 11, 2025 | Nuvalent, Inc. (NUVL) | Grant/Award | 2,837 | n/a |
| Jun 17, 2025 | ADC Therapeutics SA (ADCT) | Tax Withholding | 15,184 | $54.4K |
| Jun 5, 2025 | ADC Therapeutics SA (ADCT) | Grant/Award | 40,000 | n/a |
| May 16, 2025 | Travere Therapeutics, Inc. (TVTX) | Grant/Award | 6,500 | n/a |
| Jun 19, 2024 | ADC Therapeutics SA (ADCT) | Sale | 6,995 | $20.2K |
| Jun 14, 2024 | ADC Therapeutics SA (ADCT) | Grant/Award | 40,000 | n/a |